Form 4: Precigen Director Agee Boosts Stake with Equity Awards

Precigen Director Nancy H. Agee acquired common stock, restricted stock units, and stock options as part of her compensation on March 10, 2026.

Summary

• Nancy H. Agee, a Director of Precigen, Inc. (PGEN), acquired 16,096 shares of common stock on March 10, 2026, at a price of $3.51 per share.
• These common shares were issued in lieu of an annual retainer totaling $56,500.
• Agee also acquired 35,612 Restricted Stock Units (RSUs) on March 10, 2026, which represent a contingent right to receive one share of Precigen common stock per RSU.
• The RSUs are scheduled to vest in full on March 10, 2027.
• Additionally, Agee acquired options to purchase 41,073 shares of common stock on March 10, 2026, with an exercise price of $3.51 per share.
• These options are exercisable immediately as of March 10, 2026, and have an expiration date of March 10, 2036.
• Following these transactions, Nancy H. Agee beneficially owns 233,937 shares of common stock, 35,612 Restricted Stock Units, and options for 41,073 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their equity stake, even through compensation, generally indicates confidence in the company's future prospects and aligns management interests with shareholders.

Positives

• A director's acquisition of company equity, including common stock, RSUs, and stock options, aligns their interests with those of shareholders.
• The issuance of equity in lieu of a cash retainer demonstrates confidence in the company's future value by the director.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule for Restricted Stock Units and the expiration date for stock options.

Industry Context

StockSavvy.ai notes that providing equity compensation to directors is a standard practice across industries, designed to align the interests of board members with those of long-term shareholders. This type of transaction is a routine part of corporate governance and executive compensation structures.

Comparison to Industry Standards

• Director compensation packages frequently include a mix of cash and equity, with equity components like restricted stock units and stock options being common across biotech and pharmaceutical companies, similar to Precigen.
• The vesting schedule for RSUs (one year) and the ten-year term for stock options are within typical industry ranges for director equity awards, comparable to practices seen at companies like Intellia Therapeutics or CRISPR Therapeutics, which also utilize equity to incentivize long-term performance and retention.

Related Party Transactions

• The acquisition of common stock, restricted stock units, and stock options by Director Nancy H. Agee constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The director's increased equity stake aligns her financial interests more closely with those of the shareholders, potentially fostering decisions that enhance long-term shareholder value.

Next Steps

• The 35,612 Restricted Stock Units are scheduled to vest in full on March 10, 2027.

Key Dates

Recommendation

The filing details routine director compensation through equity awards, which is a positive for aligning interests but does not present new information significant enough to warrant a strong buy or sell recommendation. It reinforces a 'hold' stance, indicating stability in governance and director confidence.

Keywords

PGEN, Precigen, Form 4, Insider Transaction, Director Compensation, Equity Awards, Restricted Stock Units, Stock Options, Common Stock Acquisition